Plasma sLOX-1 is a potent biomarker of clinical remission and disease activity in patients with seropositive RA

Modern Rheumatology

Volumn 26, Issue 5, 2016, Pages 696-701

  Ishikawa, Masahiro ^a   Ito, Hiromu ^a   Furu, Moritoshi ^a   Hashimoto, Motomu ^a   Fujii, Takao ^a   Okahata, Akinori ^a   Mimori, Tsuneyo ^a   Matsuda, Shuichi ^a  

^a KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Anti citrullinated protein antibodies; Lectin like oxidized low density lipoprotein receptor 1; Rheumatoid arthritis; Rheumatoid factor

Indexed keywords

CARRIER PROTEINS AND BINDING PROTEINS; SLOX 1 PROTEIN; STROMELYSIN; UNCLASSIFIED DRUG; AUTOANTIBODY; BIOLOGICAL MARKER; CYCLIC CITRULLINATED PEPTIDE; CYCLOPEPTIDE; OLR1 PROTEIN, HUMAN; OXIDIZED LOW DENSITY LIPOPROTEIN RECEPTOR 1; RHEUMATOID FACTOR;

ADULT; AGED; ARTICLE; DAS28; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RHEUMATOID ARTHRITIS; VERY ELDERLY; ARTHRITIS, RHEUMATOID; BLOOD; IMMUNOLOGY; MIDDLE AGED; REMISSION; SEVERITY OF ILLNESS INDEX;

ADULT; AGED; AGED, 80 AND OVER; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; BIOMARKERS; BLOOD SEDIMENTATION; FEMALE; HUMANS; MALE; MIDDLE AGED; PEPTIDES, CYCLIC; REMISSION INDUCTION; RHEUMATOID FACTOR; SCAVENGER RECEPTORS, CLASS E; SEVERITY OF ILLNESS INDEX;

EID: 84959057995     PISSN: 14397595     EISSN: 14397609     Source Type: Journal    
DOI: 10.3109/14397595.2015.1128871     Document Type: Article

References (36)

1. J.S.Smolen, D.Aletaha, M.Koeller, M.H.Weisman, P.Emery New therapies for treatment of rheumatoid arthritis. Lancet. 2007;370(9602):1861–74.
2. A.Rubbert-Roth, A.Finckh Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy:a critical review. Arthritis Res Ther. 2009;11(Suppl 1):S1.
3. R.A.Memon, I.Staprans, M.Noor, W.M.Holleran, Y.Uchida, A.H.Moser, et al. Infection and inflammation induce LDL oxidation in vivo. Arterioscler Thromb Vasc Biol. 2000;20:1536–42.
4. J.L.Witztum, D.Steinberg Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991;88(6):1785–92.
5. S.Ogura, A.Kakino, Y.Sato, Y.Fujita, S.Iwamoto, K.Otsui, et al. Lox-1:the multifunctional receptor underlying cardiovascular dysfunction. Circ J. 2009;73:1993–9.
6. T.Sawamura, N.Kume, T.Aoyama, H.Moriwaki, H.Hoshikawa, Y.Aiba, et al. An endothelial receptor for oxidized low-density lipoprotein. Nature. 1997;386:73–7.
7. T.Nakagawa, M.Akagi, H.Hoshikawa, M.Chen, T.Yasuda, S.Mukai, et al. Lectin-like oxidized low-density lipoprotein receptor 1 mediates leukocyte infiltration and articular cartilage destruction in rat zymosan-induced arthritis. Arthritis Rheum. 2002;46:2486–94.
8. T.Kakinuma, T.Yasuda, T.Nakagawa, T.Hiramitsu, M.Akiyoshi, M.Akagi, et al. Lectin-like oxidized low-density lipoprotein receptor 1 mediates matrix metalloproteinase 3 synthesis enhanced by oxidized low-density lipoprotein in rheumatoid arthritis cartilage. Arthritis Rheum. 2004;50:3495–503.
9. N.Kume, T.Kita Lectin-Like oxidized low-density lipoprotein receptor-1 (LOX-1) in atherogenesis. Trends Cardiovasc Med. 2001;11(1):22–5.
10. N.Kume, T.Murase, H.Moriwaki, T.Aoyama, T.Sawamura, T.Masaki, et al. Inducible expression of lectin-like oxidized LDL receptor-1 in vascular endothelial cells. Circ Res. 1998;83:322–7.
11. M.Chen, T.Masaki, T.Sawamura LOX-1, the receptor for oxidized low-density lipoprotein identified from endothelial cells:Implications in endothelial dysfunction and atherosclerosis. Pharmacol Ther. 2002;95:89–100.
12. D.Li, L.Liu, H.Chen, T.Sawamura, S.Ranganathan, J.L.Mehta LOX-1 mediates oxidized low-density lipoprotein-induced expression of matrix metalloproteinases in human coronary artery endothelial cells. Circulation. 2003;107:612–17.
13. M.Ishikawa, H.Ito, M.Akiyoshi, N.Kume, H.Yoshitomi, H.Mitsuoka, et al. Lectin-like oxidized low-density lipoprotein receptor 1 signal is a potent biomarker and therapeutic target for human rheumatoid arthritis. Arthritis Rheum. 2012;64:1024–34.
14. T.Murase, N.Kume, H.Kataoka, M.Minami, T.Sawamura, T.Masaki, et al. Identification of soluble forms of lectin-like oxidized LDL receptor-1. Arterioscler Thromb Vasc Biol. 2000;20:715–20.
15. N.Kume, H.Mitsuoka, K.Hayashida, M.Tanaka, G.Kominami, T.Kita Soluble lectin-like oxidized LDL receptor-1 (sLOX-1) as a sensitive and specific biomarker for acute coronary syndrome-comparison with other biomarkers. J Cardiol. 2010;56:159–65.
16. K.Hayashida, N.Kume, T.Murase, M.Minami, D.Nakagawa, T.Inada, et al. Serum soluble lectin-like oxidized low-density lipoprotein receptor-1 levels are elevated in acute coronary syndrome a novel marker for early diagnosis. Circulation. 2005;112:812–18.
17. K.C.B.Tan, S.W.M.Shiu, Y.Wong, L.Leng, R.Bucala Soluble lectin-like oxidized low density lipoprotein receptor-1 in type 2 diabetes mellitus. J Lipid Res. 2008;49:1438–44.
18. M.Furu, M.Hashimoto, H.Ito, T.Fujii, C.Terao, N.Yamakawa, et al. Discordance and accordance between patient’s and physician’s assessments in rheumatoid arthritis. Scand J Rheumatol. 2014;43:291–5.
19. C.Terao, M.Hashimoto, M.Furu, S.Nakabo, K.Ohmura, R.Nakashima, et al. Inverse association between air pressure and rheumatoid arthritis synovitis. PLoS One 2014;9:e85376.
20. D.M.van der Heijde Plain X-rays in rheumatoid arthritis:overview of scoring methods, their reliability and applicability. Baillieres Clin Rheumatol. 1996;10:435–53.
21. N.Inoue, T.Okamura, Y.Kokubo, Y.Fujita, Y.Sato, M.Nakanishi, et al. LOX index, a novel predictive biochemical marker for coronary heart disease and stroke. Clin Chem. 2010;56:550–8.
22. C.Potter, K.L.Hyrich, A.Tracey, M.Lunt, D.Plant, D.P.M.Symmons, et al. Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. Ann Rheum Dis. 2009;68:69–74.
23. B.J.Miriovsky, K.Michaud, G.M.Thiele, J.R.O’Dell, G.W.Cannon, G.Kerr, et al. Anti-CCP antibody and rheumatoid factor concentrations predict greater disease activity in men with rheumatoid arthritis. Ann Rheum Dis. 2010;69:1292–7.
24. H.Mitsuoka, N.Kume, K.Hayashida, A.Inui-Hayashiada, Y.Aramaki, M.Toyohara, et al. Interleukin 18 stimulates release of soluble lectin-like oxidized LDL receptor-1 (sLOX-1). Atherosclerosis. 2009;202:176–82.
25. M.Yamamura, M.Kawashima, M.Taniai, H.Yamauchi, T.Tanimoto, M.Kurimoto, et al. Interferon-γ-inducing activity of interleukin-18 in the joint with rheumatoid arthritis. Arthritis Rheum. 2001;44:275–85.
26. T.Isozaki, B.J.Rabquer, J.H.Ruth, G.K.Haines, A.E.Koch ADAM-10 is overexpressed in rheumatoid arthritis synovial tissue and mediates angiogenesis. Arthritis Rheum. 2013;65:98–108.
27. H.Joo, D.Li, M.Dullaers, T.-W.Kim, D.Duluc, K.Upchurch, et al. C-type lectin-like receptor LOX-1 promotes dendritic cell-mediated class-switched B cell responses. Immunity. 2014;41:592–604.
28. L.De Rycke, I.Peene, I.E.Hoffman, E.Kruithof, A.Union, L.Meheus, et al. Rheumatoid factor and anticitrullinated protein antibodies in rheumatoid arthritis:diagnostic value, associations with radiological progression rate, and extra-articular manifestations. Ann Rheum Dis. 2004;63:1587–93.
29. E.Berglin, T.Johansson, U.Sundin, E.Jidell, G.Wadell, G.Hallmans, et al. Radiological outcome in rheumatoid arthritis is predicted by presence of antibodies against cyclic citrullinated peptide before and at disease onset, and by IgA-RF at disease onset. Ann Rheum Dis. 2006;65:453–8.
30. C.Hecht, M.Englbrecht, J.Rech, S.Schmidt, E.Araujo, K.Engelke, et al. Additive effect of anti-citrullinated protein antibodies and rheumatoid factor on bone erosions in patients with RA. Ann Rheum Dis. 2015;74(12):2151–6.
31. J.Sokolove, D.S.Johnson, L.J.Lahey, C.Wagner, D.Cheng, G.M.Thiele, et al. Rheumatoid factor as a potentiator of anti-citrullinated protein antibody-mediated inflammation in rheumatoid arthritis. Arthritis Rheumatol. 2014;66:813–21.
32. C.Terao, N.Yamakawa, K.Yano, I.M.Markusse, K.Ikari, S.Yoshida, et al. Rheumatoid factor is associated with the distribution of hand joint destruction in rheumatoid arthritis. Arthritis Rheumatol. 2015;67(12):3113–23.
33. Y.Hamamoto, H.Ito, M.Furu, M.Hashimoto, T.Fujii, M.Ishikawa, et al. Serological and progression differences of joint destruction in the wrist and the feet in rheumatoid arthritis – a cross-sectional cohort study. PLoS One. 2015;10(8):e0136611.
34. K.Sakurai, T.Sawamura Stress and vascular responses:endothelial dysfunction via lectin-like oxidized low-density lipoprotein receptor-1:close relationships with oxidative stress. J Pharmacol Sci. 2003;91:182–6.
35. W.Hueber, P.J.Utz, W.H.Robinson Autoantibodies in early arthritis:advances in diagnosis and prognostication. Clin Exp Rheumatol. 2003;21:S59–64.
36. M.Centola, G.Cavet, Y.Shen, S.Ramanujan, N.Knowlton, et al. Development of a multi-biomarker disease activity test for rheumatoid arthritis. PLoS One. 2013;8(4):e60635.